Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Outcomes Study of Epanova in High Cardiovascular Risk Statin-treated Patients With Hypertriglyceridemia
jRCT2080222896Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2015
- Modality
- Small Molecules
01
Overview
Phase 3, randomised trial of eicosapentaenoic acid + docosahexaenoic acid in hypertriglyceridemia and cardiac morbidity (2 arms), sponsored by AstraZeneca. Started Jun 2015; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
hypertriglyceridemiacardiac morbidity
Beyond the preview
Go deeper on jRCT2080222896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222896.